JP2022526799A5 - - Google Patents
Info
- Publication number
- JP2022526799A5 JP2022526799A5 JP2021558657A JP2021558657A JP2022526799A5 JP 2022526799 A5 JP2022526799 A5 JP 2022526799A5 JP 2021558657 A JP2021558657 A JP 2021558657A JP 2021558657 A JP2021558657 A JP 2021558657A JP 2022526799 A5 JP2022526799 A5 JP 2022526799A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pharmaceutical composition
- acid sequence
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025120522A JP2025148550A (ja) | 2019-04-03 | 2025-07-17 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828859P | 2019-04-03 | 2019-04-03 | |
| US62/828,859 | 2019-04-03 | ||
| US201962832032P | 2019-04-10 | 2019-04-10 | |
| US62/832,032 | 2019-04-10 | ||
| PCT/US2020/026669 WO2020206320A1 (en) | 2019-04-03 | 2020-04-03 | Formulations of protein molecules comprising iduronate 2-sulfatase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120522A Division JP2025148550A (ja) | 2019-04-03 | 2025-07-17 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526799A JP2022526799A (ja) | 2022-05-26 |
| JP2022526799A5 true JP2022526799A5 (https=) | 2023-04-03 |
| JP7715635B2 JP7715635B2 (ja) | 2025-07-30 |
Family
ID=70457135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Active JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
| JP2025120522A Pending JP2025148550A (ja) | 2019-04-03 | 2025-07-17 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120522A Pending JP2025148550A (ja) | 2019-04-03 | 2025-07-17 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220184186A1 (https=) |
| EP (1) | EP3947661A1 (https=) |
| JP (2) | JP7715635B2 (https=) |
| KR (1) | KR20220004651A (https=) |
| CN (1) | CN113785054A (https=) |
| AU (1) | AU2020252554A1 (https=) |
| BR (1) | BR112021019520A2 (https=) |
| CA (1) | CA3134538A1 (https=) |
| MA (1) | MA71657A (https=) |
| MX (1) | MX2021011612A (https=) |
| WO (1) | WO2020206320A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3699923A1 (de) * | 2019-02-20 | 2020-08-26 | Fresenius Medical Care Deutschland GmbH | Absicherungsmechanismus fuer den betrieb von medizinischen geraeten unter verwendung von verbrauchsgegenstaenden im umfeld einer dialyse |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| EP4373511A1 (en) | 2021-07-23 | 2024-05-29 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| KR20230134822A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제 |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2485761B1 (en) * | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| US20190352335A1 (en) * | 2016-12-19 | 2019-11-21 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
| CN110506055A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| JP2020528756A (ja) * | 2017-07-28 | 2020-10-01 | ハンミ ファーマシューティカル カンパニー リミテッド | イズロン酸−２−スルファターゼ結合体 |
| CR20200129A (es) * | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
-
2020
- 2020-04-03 CA CA3134538A patent/CA3134538A1/en active Pending
- 2020-04-03 CN CN202080033104.6A patent/CN113785054A/zh active Pending
- 2020-04-03 WO PCT/US2020/026669 patent/WO2020206320A1/en not_active Ceased
- 2020-04-03 BR BR112021019520A patent/BR112021019520A2/pt unknown
- 2020-04-03 EP EP20721359.6A patent/EP3947661A1/en active Pending
- 2020-04-03 MX MX2021011612A patent/MX2021011612A/es unknown
- 2020-04-03 AU AU2020252554A patent/AU2020252554A1/en active Pending
- 2020-04-03 MA MA71657A patent/MA71657A/fr unknown
- 2020-04-03 US US17/600,527 patent/US20220184186A1/en active Pending
- 2020-04-03 KR KR1020217035336A patent/KR20220004651A/ko active Pending
- 2020-04-03 JP JP2021558657A patent/JP7715635B2/ja active Active
-
2025
- 2025-07-17 JP JP2025120522A patent/JP2025148550A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526799A5 (https=) | ||
| JP7715635B2 (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| US4608364A (en) | Pharmaceutical agent for the treatment of diabetes mellitus | |
| TWI670072B (zh) | 凍乾的重組ｖｗｆ調配物 | |
| EP3238736B1 (en) | Peptides and compositions thereof for use in the prevention and treatment of macular degeneration | |
| PT1831252E (pt) | Formulações de proteínas de fusão de análogos de glp-1 | |
| CN104010658A (zh) | 使用葡甲胺稳定的依那西普制剂 | |
| Qi et al. | Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice | |
| JP2002543837A (ja) | 組換えセトマンナン結合性レクチン | |
| KR100330325B1 (ko) | 감마인터페론의안정한액체조성물 | |
| JP2023100902A (ja) | ヘモペキシン製剤 | |
| KR20230121823A (ko) | Glp-1/glp-2 이중 효능제의 약학적 조성물 | |
| KR20230121822A (ko) | Glp-1/glp-2 이중 효능제의 약학적 조성물 | |
| KR20230121824A (ko) | Glp-1/glp-2 이중 효능제의 약학적 조성물 | |
| TW202426050A (zh) | 穩定抗體組合物 | |
| US20260055163A1 (en) | Formulations comprising actriia protein variants | |
| CN113289029A (zh) | 一种单克隆抗体-细胞因子融合蛋白制剂 | |
| US10213493B2 (en) | Protein to promote blood vessel growth and uses thereof | |
| US20200390845A1 (en) | Pharmaceutical formulations of c1 esterase inhibitor | |
| CN119278029A (zh) | 包含含有α-半乳糖苷酶A的融合蛋白的冻干制剂 | |
| CN112494658A (zh) | 一种稳定的Fc融合蛋白制剂 | |
| JPH10330283A (ja) | 消化管組織再生賦活剤 | |
| RU2024121587A (ru) | ЖИДКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК, ВКЛЮЧАЮЩИЙ α-ГАЛАКТОЗИДАЗУ A | |
| CN115335074A (zh) | 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多 | |
| WO2022166918A1 (zh) | 一种抗il-5抗体制剂及其制备方法和应用 |